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can technically reproduce the procedure. Furthermore,
and most importantly, each sample was normalized to
a control DNA sample to minimize the inter-assay
variability. The inter-assay CV as determined from
this control DNA sample was 2.4%. The major focus
of our work was to introduce a well-controlled
high-throughput genotyping method to obtain reliable
estimates for relative telomere length with low
amounts of DNA. This is very similar to the perfor-
mance of a high-quality enzyme linked immuno-
sorbent assay (ELISA) for measurement of standard
biomarkers.5
With respect to the reliability of the qPCR approach
in general, we would like to point to another
very recent article on telomere attrition rates over
10 years, which had a very similar study design:
Nordfja¨ll et al.6 investigated the dependency of the
telomere attrition rate on the baseline telomere
length and found a correlation coefficient nearly
identical to ours (r¼ 0.752 in Nordfja¨ll et al.6 versus
r¼ 0.674 in Ehrlenbach et al.2). This is another strong
indication that the qPCR approach is highly reliable,
valid and replicable. In addition, recent papers in
high-ranking journals (e.g. Lancet3, PLOS Genetics6)
on telomere dynamics used the qPCR approach
instead of the TRF methodology for association
studies, thus indicating that qPCR is becoming a
state-of-the art technology for inferring relative telo-
mere length and associated phenotypic consequences.
We certainly respect that researchers like Dr Aviv
passionately advance their view. However, ‘raising
the bar on telomere biology’ does not necessarily
mean sticking to old, but still valuable, methods,
but to take a step forward towards new technologies,
thus enabling assessment of novel risk conditions in a
large number of epidemiological studies.
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We welcome the stimulating editorial by Shah
Ebrahim on our call to action to scale up the preven-
tion and control of chronic diseases.1 It is an impor-
tant contribution to efforts to ensure that chronic
diseases receive the global and national attention
commensurate with their enormous health and eco-
nomic burdens, especially in low- and middle-income
countries.2
Our call for action is 2-fold: an urgent call to imple-
ment policies where we already have the evidence on
intervention cost-effectiveness (salt reduction, tobacco
control and a multiple drug regime for managing
high cardiovascular risk); and a similar call to collect
rigorous evidence on other beneficial interventions
with the potential for making a difference in popu-
lations. Regarding the latter, the editorial confirms
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our assessment that the absolute effect size of many
interventions such as community-based health pro-
motion and changes in saturated and trans-fat
intake needs to be confirmed. This is why we called
for more rigorous evaluations of these interventions
instead of their outright scaling up—an important
distinction. Urgent operational research is needed
now to identify the best ways to implement effective
interventions in communities.
However, there is much in the editorial with which
we agree. Population growth and ageing are
key driving forces of the chronic disease pandemics.
The point is clearly made in Figure 2 of the first paper
in the Lancet chronic disease series.2 We note that for
the age group of470 years, the proportion of deaths
due to chronic diseases is projected to rise from 87.5%
in 2005 to 90.9% in 2030. We agree too that the
engagement of clinicians in the chronic disease
response will be critical, especially as the health sys-
tems strengthening agenda and the reinvigoration of
primary health care gather momentum.
Ebrahim questions the affordability of the interven-
tions proposed in the series3,4 by contrasting the pro-
jected investment needed to implement the selected
interventions across 23 low- and middle-income
countries ($58 billion over 10 years) with the eco-
nomic productivity gains associated with reducing
chronic disease deaths annually by an additional 2%
(an estimated $8 billion over 10 years). However,
these estimates are extremely conservative because
the major share of the benefits of increased chronic
disease investment comes in the form of averted or
‘delayed’ deaths (an estimated 32 million deaths over
10 years). Since we consider health to have intrinsic
value to society, we did not quantify these societal
benefits in dollar terms, but we would only need to
agree that each death averted/life saved is worth at
least $2,000—not hard when the value of life has
been put at as much as 100 times GDP per capita—
for the health system investment to pay itself back.
Further, the view that it is especially difficult to make
reallocations in countries that only commit 2–3% of
GDP to health services does not mean it cannot be
done or should not be attempted. Indeed, the case of
HIV/AIDS shows well what level of budgetary realloca-
tion can and have been achieved in resource-poor
countries. In fact, it is imperative that allocative deci-
sions in such countries are made using the best evi-
dence available to maximize health. Furthermore,
countries can and have substantially increased health
spending. Reforms in Mexico will increase public
spending on health by a full percentage point of gross
domestic product over 7 years.5 The 2008–09 budget in
India has committed to increasing health spending by
15%.6
Finally, on the importance of calls to action, The
Lancet’s experience is that these can help transform
the global policy landscape provided they are based
on sound data, trigger new collaborations based on
trust and confidence and are followed up with
events that publicly track and report on country pro-
gress with agreed indicators.7
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Within his lengthy editorial ‘Chronic diseases and
calls to action’1 devoted to chronic diseases prevention
and health promotion in low- and middle-income
countries. Shah Ebrahim questions the scientific evi-
dence for the population strategy in the prevention of
coronary heart disease within a rather provocative
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